NeoPhore achieves scientific milestones

We are pleased to announce that NeoPhore recently achieved all of its investment related scientific milestones, enabling the contingent second completion funding of £9.4m to be issued from the previously reported series B investment round. The financing will be used to further progress NeoPhore’s lead compounds from drug discovery programs targeting the DNA mismatch repair pathway.